Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Spending Less Time On INDs, More On NDAs and BLAs

Executive Summary

Five-year averages used in calculations of FY 2013 user fee rates show a decrease in time devoted to INDs and an increase in time spent on NDAs and BLAs. The average submission volume in both categories still increased.

You may also be interested in...



Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.

FDA Drug Shortage Staff Gets Higher Profile As New Reporting Requirements Begin

The 11-member staff CDER devotes to drug shortages is moving to the Office of the Center Director and will report to Deputy Director for Regulatory Programs Doug Throckmorton.

FDA Drug Review Costs Rise, But Personnel Spending Flattens

Less than 60% of the total spending on reviews was attributed to employee compensation and benefits in FY 2011. FDA says it is normal, but the figure is lower than costs seen in recent years.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS054639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel